Calyxt, Inc.

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Calix fourth quarter 2020 results conference call. During today's presentation, all parties will be in a listen only mode. Following the presentation, the conference will be open for questions. If you have a question, please press the star key followed by one on your touch tone phone. If you would like to withdraw your question, please press the star key followed by the two. If you are using speaker equipment, please lift the handset before making your selections. This conference is being recorded today, March 4th, 2021. At this time, I would like to turn the conference over to Chris Tyson, Executive Vice President of MZ North America Kalix Investor Relations Firm. Please go ahead, sir.

Thank you, and good afternoon. I would like to thank you all for taking time to join us for Kalix's fourth quarter and full year 2020 financial results conference call. Your hosts today are Dr. Eve Rebay, Executive Chair of the Board, and Bill Koshek, Chief Financial Officer. A press release detailing these results crossed the wires after the market closed today and is available on the company's website, calyx.com. Before we begin the formal presentation, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. please refer to the company's SEC filings for a list of associated risks. This presentation also includes a discussion of adjusted gross margin, net loss, net loss per share, and EBITDA. All are non-GAAP financial measures. In Calix press release and its filings with the SEC, each of which is posted on the company's website at calix.com, you will find additional disclosure regarding these non-GAAP measures. References to these non-GAAP financial measures that should be considered in addition to GAAP financial measures and should not be considered a substitute for results that are presented in accordance with GAAP. Finally, this conference call is being webcast. This webcast link is available in the investor relations section of calix.com. At this time, I would like to turn the call over to Calix Executive Chair of the Board, Yves Révé. Yves, the floor is yours.

Thank you, Chris, and thank you for joining us today for Calix's fourth quarter conference call. I'm sure many of you on today's call who have been following the Calix story as a shareholder, prospective investor, or analyst have known my roles at Calix as a board member since 2018, then interim CEO for a period of time in 2018, and most recently in the summer of 2020, I was appointed to the position of chairman of the board. My background includes a long career in biotech, including founding and more than 25 years in large pharmaceutical companies. I'm currently the chief executive officer of which is a private biotechnology company working on RNA biology. Two weeks ago, we announced the transition of my role to Executive Chair replacing CEO Gene Blum. I think it is important to note that our decision in 2020 to transition our business model was one of the primary reasons for the leadership change. Our decision represents a continuing step to focus Calix on significant innovations opportunities beyond commodity-based agriculture. We have retained a premier executive search firm, and I will help guide the CEO search on behalf of the board and support the transition once the incoming CEO is selected. On behalf of the board, we want to thank Jim for guiding Calix to a streamlined business model that can capitalize on delivering disruptive plant-based innovation. Calix has experienced a strong and productive 2020. We have redirected Calix's innovation engine to new and high-value opportunities and have built a team with the right talent mix to drive Calix's go-to-market strategies. we are solidly positioned for future growth and success. I'm excited to work directly with this excellent leadership team during this interim period. I'm also excited to announce the formation of Calix Scientific Advisory Board. We previously announced that the SAB will report to the Board of Directors of Calix and will be chaired by Dr. Dan Bortas. In addition to Dan, there will initially be three members, all of whom are world-renowned biochemistry experts, and include Dr. Anne Osborne, group leader at the John Innes Center, Dr. Elizabeth Satterley, HHMI investigator and associate professor of chemical engineering at Stanford University, and Dr. Paul Bernasconi, former global function head for molecular biology at BISF Biosciences. The Scientific Advisory Board is tasked with the strategic mission of helping Calix identify disruptive, plan-based solutions that are near-term opportunities as well as long-term, higher-risk, higher-return ideas, some of which may be realized through partnership with other commercial entities. I believe this is an exciting time for Calix and our rapidly developing disruptive plant-based technology story. Calix is a technology company focused on delivering plant-based innovations to end users across industry, including food, nutraceutical energy, and agriculture. We see our technology being applicable to other industries as well. We leverage differentiated technologies, including the talent gene editing platform, to develop product candidates. We are a leader in gene editing with exclusive access to proprietary talent technology for use in plants, which we use to successfully commercialize the first gene editing food product in the U.S. We have a development pipeline that spans multiple crops and has a substantial total addressable market of $8.8 billion. The products in the pipeline will be commercialized with partners and are targeted at critical industry dynamics, including consumer demand for specialty ingredients and supporting sustainability objectives. We also believe that we have a capital-efficient business model with multiple routes to market for our product candidates. I would now like to hand the presentation over to our CFO, Bill Koshak, who will share our 2020 highlights and walk you through our financial performance. Bill?